C
PTGX icon

Covestor’s Protagonist Therapeutics PTGX Stock Holding History

Covestor’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Buy
1,528
+653
+75% +$68.2K 0.11% 140
2026
Q1 		$92K Sell
875
-562
-39% -$49.8K 0.06% 332
2025
Q4 		$125K Buy
1,437
+447
+45% +$36.6K 0.07% 445
2025
Q3 		$66K Sell
990
-755
-43% -$42.9K 0.04% 778
2025
Q2 		$97K Sell
1,745
-342
-16% -$16.4K 0.06% 573
2025
Q1 		$101K Buy
2,087
+444
+27% +$18.6K 0.07% 485
2024
Q4 		$63K Buy
1,643
+1,612
+5,200% +$70.3K 0.04% 768
2024
Q3 		$1K Buy
31
+23
+288% +$929 ﹤0.01% 2075
2024
Q2 		$0 Buy
8
+4
+100% +$117 ﹤0.01% 2645
2024
Q1 		$0 Sell
4
-1
-20% -$27 ﹤0.01% 2631
2023
Q4 		$0 Hold
5
– – ﹤0.01% 2590
2023
Q3 		$0 Sell
5
-1
-17% -$19 ﹤0.01% 2586
2023
Q2 		$0 Sell
6
-4
-40% -$100 ﹤0.01% 2535
2023
Q1 		$0 Hold
10
– – ﹤0.01% 2461
2022
Q4 		$0 Buy
+10
New +$84 ﹤0.01% 2487
2022
Q3 		– Sell
-9
Closed – – 2457
2022
Q2 		$0 Sell
9
-2
-18% -$24 ﹤0.01% 2266
2022
Q1 		$0 Sell
11
-3
-21% -$85 ﹤0.01% 2372
2021
Q4 		$0 Buy
+14
New +$443 ﹤0.01% 2264

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Covestor's PTGX Position: Q2 2026 in Review

Covestor increased its Protagonist Therapeutics (PTGX) stake by 75% in Q2 2026, buying an estimated $68.2K and bringing the position to 1,528 shares worth $188K. The position accounts for 0.11% of the portfolio, ranked #140.

Covestor first reported a position in PTGX in Q4 2021 and has held it in 18 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Covestor held 1,528 shares of Protagonist Therapeutics worth $188K as of Q2 2026.
  • Covestor bought 653 Protagonist Therapeutics shares in Q2 2026, an estimated $68.2K.
  • Protagonist Therapeutics made up 0.11% of Covestor's portfolio in Q2 2026, its #140 holding.
  • Covestor first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.